# An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy

> **NCT01103960** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 324 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Telmisartan80mg+Amlodipine5mg
- **DRUG:** amlodipine 5mg
- **DRUG:** Telmisartan80mg+Amlodipine 5mg

## Key facts

- **NCT ID:** NCT01103960
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-08
- **Final completion:** —
- **Target enrollment:** 324 (ACTUAL)
- **Last updated:** 2014-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01103960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01103960, "An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01103960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*